Regulation - Gilead Sciences, Oncology


Current filters:

Gilead SciencesOncology

Popular Filters

US FDA approves Gilead’s Zydelig for three types of blood cancers

US FDA approves Gilead’s Zydelig for three types of blood cancers


The US Food and Drug Administration late yesterday approved Zydelig (idelalisib), a new drug from US…

BiotechnologyGilead SciencesidelalisibOncologyRegulationUSAZydelig

Germany’s IQWiG views Xofigo, Kadcyla and Eviplera


In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products, the…

Anti-viralsBayerEvipleraGermanyGilead SciencesKadcylaNorthern EuropeOncologyPharmaceuticalPricingRegulationRocheXofigo

Gilead files for US approval of iNHL drug candidate


US biotech major Gilead Sciences (Nasdaq: GILD), best known for its prowess in antivirals (HIV and hepatitis…

BiotechnologyGilead SciencesidelalisibNorth AmericaOncologyRegulation

News briefs: Genmab/GSK, Gilead and Mylan


Denmark's Genmab (OMX: GEN) yesterday received a milestone payment of 20 million Danish kroner ($3.4…

Anti-viralsBiotechnologycobicistatFinancialGenericsGenmabGilead SciencesGlaxoSmithKlineMylan LaboratoriesOncologyRegulationViramune

More cancer and HIV drugs added to Australian PBS


More than 160,000 patients will benefit directly from changes to Australia’s Pharmaceutical Benefits…

AmgenAnti-viralsAsia-PacificGilead SciencesOncologyPharmaceuticalPrezistaPricingRegulationXgeva

More news from EMA/CHMP September meeting


Following its meetings last week, the European Medicines Agency’s Committee for Medicinal Products…

Anti-viralsAntibiotics and Infectious diseasesAstellas PharmaCelgeneDificidDificlirEuropeEvipleraGilead SciencesOncologyPharmaceuticalRegulationRevlimidUCBVimpat

Back to top